Pharma IQ Members

Dr Steven Bradshaw

Drugs Pricing in France - Balancing Innovation vs Cost Containment: The New Agreement between the Government and the Pharma industry

On January 11th 2016, the Comité Economique des Produits de Santé (CEPS - Economic Committee for Health Products) signed on the behalf of the French Government a new agreement, the Accord cadre, with Les entreprises du médicament (LEEM - pharmaceutical companies association) on how to set reimbursed drugs prices for the next 3 years. The CEPS is the body that negotiates drug prices with manufacturers.

by: Dr Steven Bradshaw
Published: March 15, 2016
Tags:


Dr Steven Bradshaw

National Guidance in Spain Attracts Regional Opposition in HCV

With 19 therapeutic positioning reports (IPT: informe de posicionamiento terapéutico) now published, the focus and intention of the new Spanish health technology assessment paradigm can be reviewed. And in some quarters, the guidance has attracted substantial opposition. Our columnists Dr Steven Bradshaw and Dr David Carr discuss these issues.

by: Dr Steven Bradshaw
Published:
Tags: Spain, Spanish market, Dr Steven Bradshaw, Dr David Carr, Spanish health technology assessment paradigm


Dr Steven Bradshaw

Austerity-Driven Policy Dictates a Challenging Environment for Pharma

The austerity measures put in place as part of the &'Troika' bailout after Greece's mid-2000s financial crisis included the aim to substantially reduce national drugs spend. With the country already having one of the lowest drug prices in Europe (calculated as the average of the three lowest-price countries), additional budgetary pressure has increased the challenges for pharmaceutical companies in Greece.

by: Dr Steven Bradshaw
Published:
Tags: austerity measures, pharma, Greece


Dr Steven Bradshaw

New Cardiovascular Drug Bucks Competitive Oncology-Only Trend in UK Early Access to Medicines Scheme

One year on since the launch of the UK's Early Access to Medicines Scheme (EAMS), Novartis’ investigational heart failure drug LCZ696 (sacubitril/valsartan) has become the fifth therapy to be awarded a 'promising innovative medicine' (PIM) designation. Significantly for health technology manufacturers, LCZ696 is the first non-oncology therapy to receive a PIM, which, as Pharma IQ columnists Dr Steven Bradshaw and Dr David Carr discuss, is an important step for broadening early access to a wider range of medicines.

by: Dr Steven Bradshaw
Published:
Tags:


Dr Steven Bradshaw & Dr David Carr

Conditional Approval Opens the Door to Regenerative Medicine Therapies

Dr Steven Bradshaw and Dr David Carr of Market Access Solutions (MKTXS) discuss a new framework for conditional (pre-full license) approval of regenerative therapies in Japan … Legislation that came into force in November 2014 is paving the way for a potential influx of regenerative medicines into the Japanese market. The Pharmaceuticals, Medical Devices and Other Therapeutic Products (PMD)... Read more

by: Dr Steven Bradshaw & Dr David Carr
Published: April 13, 2015
Tags: